ONTARGET: Use of ramipril, telmisartan, or both in patients with high cardiovascular risks

被引：0
|
作者：
HoWon Lee
Amgad N. Makaryus
Samy I. McFarlane
机构：
来源：
Current Diabetes Reports | 2009年 / 9卷 / 3期
关键词：
Chronic Heart Failure; Valsartan; Ramipril; Candesartan; Telmisartan;
D O I：
10.1007/s11892-009-0030-9
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：185 / 187
页数：2
相关论文
共 50 条
  • [21] EFFECTS OF RAMIPRIL, TELMISARTAN AND THEIR COMBINATION ON AMBULATORY BLOOD PRESSURE IN AN ONTARGET SUBSTUDY
    Mancia, G.
    Parati, G.
    Bilo, G.
    Giglio, A.
    Gao, P.
    Verdecchia, P.
    Redon, J.
    Sleight, P.
    Fagard, R. H.
    Yusuf, S.
    Teo, K.
    JOURNAL OF HYPERTENSION, 2009, 27 : S168 - S168
  • [22] The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: Results from the ONTARGET trial
    Heerspink, Hiddo J. Lambers
    Gao, Peggy
    de Zeeuw, Dick
    Clase, Catherine
    Dagenais, Gilles R.
    Sleight, Peter
    Lonn, Eva
    Teo, Koon T.
    Yusuf, Salim
    Mann, Johannes F.
    EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2014, 21 (03) : 299 - 309
  • [23] What is better in patients at high risk for vascular events? Telmisartan, Ramipril, or a combination of both?
    Pavlicek, V.
    DIABETOLOGE, 2008, 4 (04): : 293 - 294
  • [24] Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study):: a multicentre, randomised, double-blind, controlled trial
    Mann, Johannes F. E.
    Schmieder, Roland E.
    McQueen, Matthew
    Dyal, Leanne
    Schumacher, Helmut
    Pogue, Janice
    Wang, Xingyu
    Maggioni, Aldo
    Budaj, Andrzej
    Chaithiraphan, Suphachai
    Dickstein, Kenneth
    Keltai, Matyas
    Metsarinne, Kaj
    Oto, Ali
    Parkhomenko, Alexander
    Piegas, Leopoldo S.
    Svendsen, Tage L.
    Teo, Koon K.
    Yusuf, Salim
    LANCET, 2008, 372 (9638): : 547 - 553
  • [25] Impact of Sex on Cardiovascular Outcome in Patients at High Cardiovascular Risk Analysis of the Telmisartan Randomized Assessment Study in ACE-Intolerant Subjects With Cardiovascular Disease (TRANSCEND) and the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial (ONTARGET)
    Kappert, Kai
    Boehm, Michael
    Schmieder, Roland
    Schumacher, Helmut
    Teo, Koon
    Yusuf, Salim
    Sleight, Peter
    Unger, Thomas
    CIRCULATION, 2012, 126 (08) : 934 - U76
  • [26] Left Ventricular Mass and Volume With Telmisartan, Ramipril, or Combination in Patients With Previous Atherosclerotic Events or With Diabetes Mellitus (from the ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial [ONTARGET])
    Cowan, Brett R.
    Young, Alistair A.
    Anderson, Craig
    Doughty, Robert N.
    Krittayaphong, Rungroj
    Lonn, Eva
    Marwick, Thomas H.
    Reid, Chris M.
    Sanderson, John E.
    Schmieder, Roland E.
    Teo, Koon
    Wadham, Angela K.
    Worthley, Stephen G.
    Yu, Cheuk-Man
    Yusuf, Salim
    Jennings, Garry L.
    AMERICAN JOURNAL OF CARDIOLOGY, 2009, 104 (11): : 1484 - 1489
  • [27] Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating Telmisartan, Ramipril, and their combination in high-risk patients: The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials
    Teo, KK
    AMERICAN HEART JOURNAL, 2004, 148 (01) : 52 - 61
  • [28] The combined effects of telmisartan and ramipril on hypertension and cardiovascular injury
    Lee, Do-Hyung
    Kim, Min-Tae
    Lee, Hyung-Won
    Han, Joo-Hui
    Myung, Chang-Seon
    JOURNAL OF PHARMACEUTICAL INVESTIGATION, 2022, 52 (04) : 443 - 451
  • [29] The combined effects of telmisartan and ramipril on hypertension and cardiovascular injury
    Do-Hyung Lee
    Min-Tae Kim
    Hyung-Won Lee
    Joo-Hui Han
    Chang-Seon Myung
    Journal of Pharmaceutical Investigation, 2022, 52 : 443 - 451
  • [30] Ambulatory Blood Pressure Values in the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET)
    Mancia, Giuseppe
    Parati, Gianfranco
    Bilo, Grzegorz
    Gao, Peggy
    Fagard, Robert
    Redon, Josep
    Czuriga, Istvan
    Polak, Martin
    Ribeiro, Jose M.
    Sanchez, Ramiro
    Trimarco, Bruno
    Verdecchia, Paolo
    van Mieghem, Walter
    Teo, Koon
    Sleight, Peter
    Yusuf, Salim
    HYPERTENSION, 2012, 60 (06) : 1400 - 1406
12345